Prostate Cancer Clinical Trial

Continued Access of Focal MR-Guided Focused Ultrasound for Localized Intermediate Risk Prostate Lesions

Summary

This extended clinical investigation is a multicenter, prospective, single arm study intended to provide continued access of the Exablate Model 2100 device (Exablate Prostate) to patients for treatment of prostate lesions and collect additional safety and effectiveness data during the 510(k) preparation and review period.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Biopsy proven adenocarcinoma of the prostate
Intermediate risk, organ-confined prostate cancer (T1a up to T2b) and voluntarily chooses Exablate, who may currently be on watchful waiting or active surveillance and not in need of imminent radical therapy
Up to 2 MRI visible Gleason 7 confirmed on mapping prostate biopsy that Investigator deems treatable within a single treatment session; may have secondary Gleason 6 on ipsilateral or contralateral side confirmed with biopsy and/or MRI
PSA less than or equal to 20ng/mL

Exclusion Criteria:

Evidence of distant prostate cancer including lymph node involvement and/or metastasis of cancer
Subject undergoing androgen deprivation therapy, initiating any new medication that can affect PSA, or history of bilateral orchiectomy
Active bladder cancer, active UTI, or untreated prostatitis
Untreated urethral stricture/bladder neck contracture
Prostate-specific chemotherapy, brachytherapy, cryotherapy, photodynamic therapy, radical prostatectomy, or focal therapy (excluding FUS); or any prior radiation therapy to the pelvis for prostate cancer or any other malignancy
Subjects with pathology or implants that may adversely impact treatment due to acoustics, imaging, or safe probe insertion
Subject not able or willing to tolerate the required prolonged stationary supine position during treatment
Contraindications to MRI

Study is for people with:

Prostate Cancer

Estimated Enrollment:

14

Study ID:

NCT03998657

Recruitment Status:

Active, not recruiting

Sponsor:

InSightec

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 5 Locations for this study

See Locations Near You

Stanford University School of Medicine
Stanford California, 94305, United States
Sperling Prostate Center
Delray Beach Florida, 33445, United States
Brigham & Women's Hospital
Boston Massachusetts, 02115, United States
Mayo Clinic
Rochester Minnesota, 55905, United States
Memorial Sloan-Kettering Cancer Center
New York New York, 10065, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Estimated Enrollment:

14

Study ID:

NCT03998657

Recruitment Status:

Active, not recruiting

Sponsor:


InSightec

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.